Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy
about
P1343
Sub-lethal radiation enhances anti-tumor immunotherapy in a transgenic mouse model of pancreatic cancerUse of recombinant lentivirus pseudotyped with vesicular stomatitis virus glycoprotein G for efficient generation of human anti-cancer chimeric T cells by transduction of human peripheral blood lymphocytes in vitro.Implication of indolamine 2,3 dioxygenase in the tolerance toward fetuses, tumors, and allograftsTargeting and utilizing primary tumors as live vaccines: changing strategiesImmunotherapy in gastric cancerFacilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 BlockadeA new therapy for highly effective tumor eradication using HVJ-E combined with chemotherapy.Why do B cell lymphoma fail to elicit clinically sufficient T cell immune responses?Why did your mother reject you? Immunogenetic determinants of the response to environmental selective pressure expressed at the uterine level.Autoaggression and tumor rejection: it takes more than self-specific T-cell activation.Cross-presentation of tumour antigens: evaluation of threshold, duration, distribution and regulation.Cytotoxic T-lymphocyte epitope immunodominance in the control of choroid plexus tumors in simian virus 40 large T antigen transgenic mice.Immune selection in neoplasia: towards a microevolutionary model of cancer development.Targeting inhibitory pathways in cancer immunotherapy.TGF-beta-based immunotherapy for cancer: breaching the tumor firewall.Early expression of stem cell-associated genes within the CD8 compartment after treatment with a tumor vaccineBystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase.Quantitative imaging of the T cell antitumor response by positron-emission tomography.Tregs and rethinking cancer immunotherapy.Spinning molecular immunology into successful immunotherapy.Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors.Dendritic cells purified from myeloma are primed with tumor-specific antigen (idiotype) and activate CD4+ T cells.Adoptive-cell-transfer therapy for the treatment of patients with cancerExpression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes.CD4 cells can be more efficient at tumor rejection than CD8 cellsLocal expression of secondary lymphoid tissue chemokine delivered by adeno-associated virus within the tumor bed stimulates strong anti-liver tumor immunity.Proteasome inhibition blocks NF-κB and ERK1/2 pathways, restores antigen expression, and sensitizes resistant human melanoma to TCR-engineered CTLsExpression of death receptor 6 by ovarian tumors in laying hens, a preclinical model of spontaneous ovarian cancer.Induced sensitization of tumor stroma leads to eradication of established cancer by T cells.Spontaneous tumor rejection by cbl-b-deficient CD8+ T cellsStimulation of autoimmunity by toll-like receptor ligands.Cytotoxic T lymphocytes to an unmutated tumor rejection antigen P1A: normal development but restrained effector function in vivo.Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance.Escaping high viral load exhaustion: CD8 cells with altered tetramer binding in chronic hepatitis B virus infection.Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.Tumor-infiltrating T lymphocytes: friends or foes?Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors.The tumor-draining lymph node as an immune-privileged site.Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases.Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness.
P2860
Q24793123-5336FA2D-93FA-44DC-9F1A-DB8857CE0A62Q25257888-939C7FCF-03D3-4170-8E52-ABE90CAE66C4Q26825202-3B61F74B-595C-42C7-A08B-2563F96424CEQ27009348-74DC2AA8-0971-47D0-9600-A4E155CAEB04Q27010472-B853B37C-4C34-40E7-9E9F-E7226B52724BQ28119095-734FC5A8-9428-4D49-9D20-14E339013BDCQ33299767-FAF53E22-079E-4B64-9D22-DD5CF272E175Q33536297-47102BDD-A597-41D2-BA9F-A0CE167BBA95Q33546312-30744472-BAD5-4F2E-BD06-7A889A9F2152Q33713362-3FE5B8D9-5189-4D2C-9EE1-55407619FC32Q33778847-D4B9D159-DAC9-4CBF-A9D6-C18FFE6CADA8Q33815865-747FF5E3-6215-4182-AF45-CFDA529A7746Q33948688-033D0E47-8A7C-4B81-91DF-C12EA9533DBBQ33950640-75CE833D-2302-46ED-BF71-1ADE5F41E403Q34057799-1F17DF92-1781-41E9-8DAB-EA4EA5E8E809Q34110774-923B16B7-F6C3-48F4-9866-C859901CC449Q34243372-CEEFF511-9C9D-427F-A4B8-B4CEAE203A80Q34330047-26C0733D-738D-4C5B-BF29-A50019A9A7EDQ34625147-22CB012D-C888-4F45-ADFF-9BC54C184DB1Q34632056-972DF4DE-2D85-42C5-A54B-DBDD07CB7BF2Q34789146-259C408B-B79A-4A6A-8E27-A4FD9B5E0725Q35079386-FFA7DD4C-B76B-4F22-A81C-0B2E631F3748Q35210008-7A850B80-C524-46C0-BC65-EDBECAD8440FQ35835489-7459E7AA-899E-47F1-8D2D-957B220E0185Q35839925-0AB0EF88-F2F8-46F2-B523-737CDB79938EQ35947942-6DCFDD53-1643-4335-AEAE-2A00FE95F006Q36028423-7AE5657A-AF32-41B4-B844-D4DC77D60922Q36199847-27A2FA75-6336-4502-852E-41F54AAFD624Q36228950-6452F2DB-A518-4400-8F8F-7392D0CE8646Q36229277-9C5E3979-569B-4D33-BCA5-852EFFE6D40DQ36292615-3C5D598C-E550-4A86-B91E-E0CAF9BC9955Q36367821-5FEB79C1-4DA8-4E59-B0FA-1759CE710B36Q36369913-3727373F-070D-4D15-970F-66327E390968Q36370173-292F7810-4380-40E6-ACF8-C0EDD670A46CQ36371632-CF617F09-0D8A-4EA0-9FD8-F3F25A56F9ECQ36381918-EAFE734C-8B65-4935-9779-C3AB26A8638DQ36402716-655A2E24-6088-4846-9AAB-491211424E17Q36593753-033A0BA0-FFCC-4966-9047-582F5E168D78Q36663505-F52C9971-4493-4E59-BADE-B0DBE1870877Q36742295-ED236A40-297F-4E39-9B48-AEB0BA5DCA29
P2860
Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh
1997年學術文章
@zh-hant
name
Antigenic cancer cells grow pr ...... exhaustion or systemic anergy
@ast
Antigenic cancer cells grow pr ...... exhaustion or systemic anergy
@en
type
label
Antigenic cancer cells grow pr ...... exhaustion or systemic anergy
@ast
Antigenic cancer cells grow pr ...... exhaustion or systemic anergy
@en
prefLabel
Antigenic cancer cells grow pr ...... exhaustion or systemic anergy
@ast
Antigenic cancer cells grow pr ...... exhaustion or systemic anergy
@en
P2093
P2860
P356
P1476
Antigenic cancer cells grow pr ...... exhaustion or systemic anergy
@en
P2093
C T Siegel
H Schreiber
J A Bluestone
P E Fields
P2860
P304
P356
10.1084/JEM.186.2.229
P407
P4510
P577
1997-07-01T00:00:00Z